Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

GPS Test Result Explorer

Increase your understanding of how the Oncotype DX Genomic Prostate Score® (GPS) test refines patient risk levels to connect you to more informed treatment decisions.

Select a National Comprehensive Cancer Network® (NCCN®) risk group in step 1 and then add a GPS result in step 2 to see how the combination gives you a more informed risk across multiple clinical endpoints and individualized risk factors.

ddddddd

STEP 1: SELECT AN NCCN RISK GROUP ?
×

NCCN Guidelines Chart

Very Low
Low
Favorable Intermediate
Unfavorable Intermediate 3+4
Unfavorable Intermediate 4+3
High
STEP 2: SELECT A GPS RESULT ?The average GPS result for the NCCN Very Low Risk group is 24. Scores 60-100 are currently not available for this demo.
?This is a demo with limited functionality. Steps may lock after selection.
0
10
20
30
40
50
60
GPS Result Explorer - Patient's GPS result is: 0
GPS
12
GPS
0
24
61
100
(c)
Group Average 24
GPS
12
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
7%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 7% (95% CI: 4% - 14%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 6%)
High-Grade Disease
(Gleason ≥ 4+3)
5% 0% 100% (95% CI: 2% - 10%)
Non-Organ Confined Disease
(pT3+)
3% 0% 100% (95% CI: 1% - 8%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
12
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
7%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 6%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
7%
High-Grade Disease
(Gleason ≥ 4+3)
5%
(95% CI: 2% - 10%)
Non-Organ Confined Disease
(pT3+)
3%
(95% CI: 1% - 8%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 7% (95% CI: 4% - 14%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
10
GPS
0
24
61
100
(c)
Group Average 24
GPS
10
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
7%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 7% (95% CI: 3% - 13%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 6%)
High-Grade Disease
(Gleason ≥ 4+3)
4% 0% 100% (95% CI: 2% - 10%)
Non-Organ Confined Disease
(pT3+)
3% 0% 100% (95% CI: 1% - 8%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
10
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
7%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 6%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
7%
(95% CI: 3% - 13%)
High-Grade Disease
(Gleason ≥ 4+3)
4%
(95% CI: 2% - 10%)
Non-Organ Confined Disease
(pT3+)
3%
(95% CI: 1% - 8%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 7% (95% CI: 3% - 13%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
20
GPS
0
24
61
100
(c)
Group Average 24
GPS
20
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
10%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 10% (95% CI: 5% - 19%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 7%)
High-Grade Disease
(Gleason ≥ 4+3)
6% 0% 100% (95% CI: 3% - 14%)
Non-Organ Confined Disease
(pT3+)
6% 0% 100% (95% CI: 3% - 13%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
20
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
10%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 7%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
10%
(95% CI: 5% - 19%)
High-Grade Disease
(Gleason ≥ 4+3)
6%
(95% CI: 3% - 14%)
Non-Organ Confined Disease
(pT3+)
6%
(95% CI: 3% - 13%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 10% (95% CI: 5% - 19%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
30
GPS
0
24
61
100
(c)
Group Average 24
GPS
30
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
15%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 15% (95% CI: 8% - 26%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 8%)
High-Grade Disease
(Gleason ≥ 4+3)
9% 0% 100% (95% CI: 4% - 20%)
Non-Organ Confined Disease
(pT3+)
8% 0% 100% (95% CI: 3% - 17%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
30
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
15%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 8%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
15%
(95% CI: 8% - 26%)
High-Grade Disease
(Gleason ≥ 4+3)
9%
(95% CI: 4% - 20%)
Non-Organ Confined Disease
(pT3+)
8%
(95% CI: 3% - 17%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 15% (95% CI: 8% - 26%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
40
GPS
0
24
61
100
(c)
Group Average 24
GPS
40
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
22%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 22% (95% CI: 12% - 37%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 10%)
High-Grade Disease
(Gleason ≥ 4+3)
14% 0% 100% (95% CI: 6% - 27%)
Non-Organ Confined Disease
(pT3+)
15% 0% 100% (95% CI: 7% - 30%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
40
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
22%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 10%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
22%
(95% CI: 12% - 37%)
High-Grade Disease
(Gleason ≥ 4+3)
14%
(95% CI: 6% - 27%)
Non-Organ Confined Disease
(pT3+)
15%
(95% CI: 7% - 30%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 22% (95% CI: 12% - 37%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
50
GPS
0
24
61
100
(c)
Group Average 24
GPS
50
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
31%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 31% (95% CI: 17% - 49%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
2% 0% 100% (95% CI: <1% - 14%)
High-Grade Disease
(Gleason ≥ 4+3)
19% 0% 100% (95% CI: 9% - 38%)
Non-Organ Confined Disease
(pT3+)
15% 0% 100% (95% CI: 7% - 30%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
50
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
31%
MODERATE LIKELIHOOD 26-59%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
2%
(95% CI: <1% - 14%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
31%
(95% CI: 17% - 49%)
High-Grade Disease
(Gleason ≥ 4+3)
19%
(95% CI: 9% - 38%)
Non-Organ Confined Disease
(pT3+)
15%
(95% CI: 7% - 30%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 31% (95% CI: 17% - 49%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
60
GPS
0
24
61
100
(c)
Group Average 24
GPS
60
GPS
0
24
61
100
(c)
Group Average 24
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
42%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 42% (95% CI: 24% - 62%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
2% 0% 100% (95% CI: <1% - 18%)
High-Grade Disease
(Gleason ≥ 4+3)
27% 0% 100% (95% CI: 12% - 50%)
Non-Organ Confined Disease
(pT3+)
28% 0% 100% (95% CI: 12% - 53%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
60
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
42%
MODERATE LIKELIHOOD 26-59%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
2%
(95% CI: <1% - 18%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
42%
(95% CI: 24% - 62%)
High-Grade Disease
(Gleason ≥ 4+3)
27%
(95% CI: 12% - 50%)
Non-Organ Confined Disease
(pT3+)
28%
(95% CI: 12% - 53%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 42% (95% CI: 24% - 62%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 13% of patients with NCCN Very Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

STEP 2: SELECT A GPS RESULT ?The average GPS result for the NCCN Low Risk group is 25. Scores 60-100 are currently not available for this demo.
?This is a demo with limited functionality. Steps may lock after selection.
0
10
20
30
40
50
60
GPS Result Explorer - Patient's GPS result is: 0
GPS
12
GPS
0
25
61
100
(c)
Group Average 25
GPS
12
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
16%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 16% (95% CI: 12% - 21%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 6%)
High-Grade Disease
(Gleason ≥ 4+3)
9% 0% 100% (95% CI: 6% - 13%)
Non-Organ Confined Disease
(pT3+)
9% 0% 100% (95% CI: 6% - 12%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
12
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
16%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 6%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
16%
(95% CI: 12% - 21%)
High-Grade Disease
(Gleason ≥ 4+3)
9%
(95% CI: 6% - 13%)
Non-Organ Confined Disease
(pT3+)
9%
(95% CI: 6% - 12%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 16% (95% CI: 12% - 21%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
10
GPS
0
25
61
100
(c)
Group Average 25
GPS
10
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
15%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 15% (95% CI: 11% - 20%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 6%)
High-Grade Disease
(Gleason ≥ 4+3)
8% 0% 100% (95% CI: 6% - 12%)
Non-Organ Confined Disease
(pT3+)
8% 0% 100% (95% CI: 5% - 12%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
10
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
15%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 6%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
15%
(95% CI: 11% - 20%)
High-Grade Disease
(Gleason ≥ 4+3)
8%
(95% CI: 6% - 12%)
Non-Organ Confined Disease
(pT3+)
8%
(95% CI: 5% - 12%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 15% (95% CI: 11% - 20%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
20
GPS
0
25
61
100
(c)
Group Average 25
GPS
20
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
21%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 21% (95% CI: 17% - 26%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 7%)
High-Grade Disease
(Gleason ≥ 4+3)
12% 0% 100% (95% CI: 9% - 16%)
Non-Organ Confined Disease
(pT3+)
13% 0% 100% (95% CI: 10% - 17%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
20
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
21%
LOW LIKELIHOOD ≤25%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 7%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
21%
(95% CI: 17% - 26%)
High-Grade Disease
(Gleason ≥ 4+3)
12%
(95% CI: 9% - 16%)
Non-Organ Confined Disease
(pT3+)
13%
(95% CI: 10% - 17%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 21% (95% CI: 17% - 26%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
30
GPS
0
25
61
100
(c)
Group Average 25
GPS
30
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
30%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 30% (95% CI: 25% - 35%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 8%)
High-Grade Disease
(Gleason ≥ 4+3)
18% 0% 100% (95% CI: 14% - 22%)
Non-Organ Confined Disease
(pT3+)
21% 0% 100% (95% CI: 17% - 26%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
30
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
30%
MODERATE LIKELIHOOD 26-59%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 8%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
30%
(95% CI: 25% - 35%)
High-Grade Disease
(Gleason ≥ 4+3)
18%
(95% CI: 14% - 22%)
Non-Organ Confined Disease
(pT3+)
21%
(95% CI: 17% - 26%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 30% (95% CI: 25% - 35%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
40
GPS
0
25
61
100
(c)
Group Average 25
GPS
40
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
42%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 42% (95% CI: 35% - 49%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1% 0% 100% (95% CI: <1% - 10%)
High-Grade Disease
(Gleason ≥ 4+3)
25% 0% 100% (95% CI: 19% - 31%)
Non-Organ Confined Disease
(pT3+)
34% 0% 100% (95% CI: 27% - 41%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
40
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
42%
MODERATE LIKELIHOOD 26-59%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
1%
(95% CI: <1% - 10%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
42%
(95% CI: 35% - 49%)
High-Grade Disease
(Gleason ≥ 4+3)
25%
(95% CI: 19% - 31%)
Non-Organ Confined Disease
(pT3+)
34%
(95% CI: 27% - 41%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 42% (95% CI: 35% - 49%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
50
GPS
0
25
61
100
(c)
Group Average 25
GPS
50
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
54%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 54% (95% CI: 44% - 63%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
<1% 0% 100% (95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
2% 0% 100% (95% CI: <1% - 14%)
High-Grade Disease
(Gleason ≥ 4+3)
34% 0% 100% (95% CI: 25% - 44%)
Non-Organ Confined Disease
(pT3+)
48% 0% 100% (95% CI: 37% - 59%)
GPS Result Explorer - Patient's GPS result is: 0
GPS
50
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
54%
MODERATE LIKELIHOOD 26-59%
The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

Clinical Endpoints and Individualized Risk
Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
&lt;1%
(95% CI: <1% - <1%)
Metastasis Within 10 Years After Radical Prostatectomyg ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
2%
(95% CI: <1% - 14%)
Adverse Pathology ?
In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
(Gleason 4+3 and/or pT3+)
54%
(95% CI: 44% - 63%)
High-Grade Disease
(Gleason ≥ 4+3)
34%
(95% CI: 25% - 44%)
Non-Organ Confined Disease
(pT3+)
48%
(95% CI: 37% - 59%)
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 54% (95% CI: 44% - 63%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

Learn more about the Oncotype DX Genomic Prostate Score test.

 


 

GPS Result Explorer - Patient's GPS result is: 0
GPS
60
GPS
0
25
61
100
(c)
Group Average 25
GPS
60
GPS
0
25
61
100
(c)
Group Average 25
Likelihood of Adverse Pathology at Radical Prostatectomy(d)
65%
LOW LIKELIHOOD ≤25%
MODERATE LIKELIHOOD 26-59%
HIGH LIKELIHOOD ≥60%
Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 65% (95% CI: 52% - 76%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a high likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3
  • The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    <1% 0% 100% (95% CI: <1% - <1%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    2% 0% 100% (95% CI: <1% - 18%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    44% 0% 100% (95% CI: 31% - 58%)
    Non-Organ Confined Disease
    (pT3+)
    62% 0% 100% (95% CI: 48% - 74%)
    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    60
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    65%
    HIGH LIKELIHOOD ≥60%
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints and Individualized Risk
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    &lt;1%
    (95% CI: <1% - <1%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    2%
    (95% CI: <1% - 18%)
    Adverse Pathology ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    (Gleason 4+3 and/or pT3+)
    65%
    (95% CI: 52% - 76%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    44%
    (95% CI: 31% - 58%)
    Non-Organ Confined Disease
    (pT3+)
    62%
    (95% CI: 48% - 74%)
    Clinical Interpretation(e)
  • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 65% (95% CI: 52% - 76%) based on the combined GPS result and NCCN risk group.
  • Data from the clinical validation studies suggest this patient has a high likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
  • In our clinical validation studies, 29% of patients with NCCN Low risk prostate cancer had adverse pathology at radical prostatectomy.2,3

  • Learn more about the Oncotype DX Genomic Prostate Score test.

     


     

    STEP 2: SELECT A GPS RESULT ?The average GPS result for the NCCN Intermediate Risk group is 32. Scores 60-100 are currently not available for this demo.
    ?This is a demo with limited functionality. Steps may lock after selection.
    0
    10
    20
    30
    40
    50
    60
    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    12
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    GPS
    12
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    24%
    LOW LIKELIHOOD ≤25%
    MODERATE LIKELIHOOD 26-59%
    HIGH LIKELIHOOD ≥60%
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 24% (95% CI: 17% - 33%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    <1% 0% 100% (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    4% 0% 100% (95% CI: 1% - 17%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    12% 0% 100% (95% CI: 7% - 18%)
    Non-Organ Confined Disease
    (pT3+)
    10% 0% 100% (95% CI: 6% - 15%)
    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    12
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    24%
    LOW LIKELIHOOD ≤25%
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints and Individualized Risk
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    &lt;1%
    (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    4%
    (95% CI: 1% - 17%)
    Adverse Pathology ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    (Gleason 4+3 and/or pT3+)
    24%
    (95% CI: 17% - 33%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    12%
    (95% CI: 7% - 18%)
    Non-Organ Confined Disease
    (pT3+)
    10%
    (95% CI: 6% - 15%)
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 24% (95% CI: 17% - 33%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3

    Learn more about the Oncotype DX Genomic Prostate Score test.

     


     

    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    10
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    GPS
    10
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    22%
    LOW LIKELIHOOD ≤25%
    MODERATE LIKELIHOOD 26-59%
    HIGH LIKELIHOOD ≥60%
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 22% (95% CI: 15% - 31%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    1% 0% 100% (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    4% 0% 100% (95% CI: 1% - 17%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    11% 0% 100% (95% CI: 6% - 17%)
    Non-Organ Confined Disease
    (pT3+)
    9% 0% 100% (95% CI: 5% - 14%)
    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    10
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    22%
    LOW LIKELIHOOD ≤25%
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints and Individualized Risk
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    1%
    (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    4%
    (95% CI: 1% - 17%)
    Adverse Pathology ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    (Gleason 4+3 and/or pT3+)
    22%
    (95% CI: 15% - 31%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    11%
    (95% CI: 6% - 17%)
    Non-Organ Confined Disease
    (pT3+)
    9%
    (95% CI: 5% - 14%)
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 22% (95% CI: 15% - 31%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a low likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3

    Learn more about the Oncotype DX Genomic Prostate Score test.

     


     

    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    20
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    GPS
    20
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    31%
    LOW LIKELIHOOD ≤25%
    MODERATE LIKELIHOOD 26-59%
    HIGH LIKELIHOOD ≥60%
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 31% (95% CI: 24% - 39%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    1% 0% 100% (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    4% 0% 100% (95% CI: 1% - 16%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    15% 0% 100% (95% CI: 11% - 22%)
    Non-Organ Confined Disease
    (pT3+)
    14% 0% 100% (95% CI: 10% - 20%)
    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    20
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    31%
    MODERATE LIKELIHOOD 26-59%
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints and Individualized Risk
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    1%
    (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    4%
    (95% CI: 1% - 16%)
    Adverse Pathology ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    (Gleason 4+3 and/or pT3+)
    31%
    (95% CI: 24% - 39%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    15%
    (95% CI: 11% - 22%)
    Non-Organ Confined Disease
    (pT3+)
    14%
    (95% CI: 10% - 20%)
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 31% (95% CI: 24% - 39%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3

    Learn more about the Oncotype DX Genomic Prostate Score test.

     


     

    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    30
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    GPS
    30
    GPS
    0
    28
    61
    100
    (c)
    Group Average 28
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    40%
    LOW LIKELIHOOD ≤25%
    MODERATE LIKELIHOOD 26-59%
    HIGH LIKELIHOOD ≥60%
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 40% (95% CI: 33% - 48%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints Individualized Risk (95% Confidence interval [CI])
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    1% 0% 100% (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    5% 0% 100% (95% CI: 1% - 17%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    22% 0% 100% (95% CI: 16% - 29%)
    Non-Organ Confined Disease
    (pT3+)
    22% 0% 100% (95% CI: 16% - 28%)
    GPS Result Explorer - Patient's GPS result is: 0
    GPS
    30
    Likelihood of Adverse Pathology at Radical Prostatectomy(d)
    40%
    MODERATE LIKELIHOOD 26-59%
    The GPS Results Explorer is for illustrative purposes only. It is not intended to generate results and reports for actual patients. Actual GPS test reports may vary. This tool is not a substitute for the GPS test report. For additional information or to set up an interactive online account please contact your Exact Sciences sales representative or call 1-844-232-4719.

    The Oncotype DX Genomic Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR.

    The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patients with localized prostate cancer.2,3,4

    Clinical Endpoints and Individualized Risk
    Prostate Cancer Death Within 10 Years After Radical Prostatectomy ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    1%
    (95% CI: <1% - 2%)
    Metastasis Within 10 Years After Radical Prostatectomyg ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group. In the clinical validation study, metastasis was determined by imaging or biopsy.
    5%
    (95% CI: 1% - 17%)
    Adverse Pathology ?
    In the clinical validation study, all patients received radical prostatectomy. The risk estimates provided are based on the patient’s GPS result and NCCN risk group.
    (Gleason 4+3 and/or pT3+)
    40%
    (95% CI: 33% - 48%)
    High-Grade Disease
    (Gleason ≥ 4+3)
    22%
    (95% CI: 16% - 29%)
    Non-Organ Confined Disease
    (pT3+)
    22%
    (95% CI: 16% - 28%)
    Clinical Interpretation(e)
    • This patient’s likelihood of adverse pathology (higher Gleason Score and/or extraprostatic disease(f)) at radical prostatectomy is 40% (95% CI: 33% - 48%) based on the combined GPS result and NCCN risk group.
    • Data from the clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies.2,3
    • In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy.2,3
    GPS Result Related Resources: ?
    View resources related to the GPS result chosen above.